Mainz Biomed B.V. (MYNZ)

DE — Healthcare Sector
Peers: APDN  STIM  PRE  FONR  GTH  OLK  MDXH  NOTV  STRRP  LAB  BDSX  NDRA  SERA  DRIO  BNR  LMDX 

Automate Your Wheel Strategy on MYNZ

With Tiblio's Option Bot, you can configure your own wheel strategy including MYNZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MYNZ
  • Rev/Share 0.9233
  • Book/Share 6.2449
  • PB 0.3171
  • Debt/Equity 0.541
  • CurrentRatio 1.3184
  • ROIC -1.9286

 

  • MktCap 7553409.0
  • FreeCF/Share -17.914
  • PFCF -0.4355
  • PE -0.0885
  • Debt/Assets 0.2471
  • DivYield 0
  • ROE -22.6965

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation MYNZ Maxim Group -- Buy -- $14 Feb. 14, 2025

News

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
MYNZ
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Read More
image for news Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
MYNZ
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Read More
image for news Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
MYNZ
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Read More
image for news Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Mainz Biomed Expands into Switzerland with labor team w
MYNZ
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Read More
image for news Mainz Biomed Expands into Switzerland with labor team w
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
MYNZ
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Read More
image for news Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

About Mainz Biomed B.V. (MYNZ)

  • IPO Date 2021-11-05
  • Website https://mainzbiomed.com
  • Industry Medical - Diagnostics & Research
  • CEO Mr. Guido Baechler
  • Employees 19

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.